Related Experiment Video
Updated: Jun 12, 2025
07:50
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
1.6K
Rifampin in device-related infections: Assessing the modern evidence.
Spencer H Durham1, Elizabeth W Covington2, Megan Z Roberts1
1Auburn University Harrison College of Pharmacy, Huntsville, AL, USA.
Summary
Rifampin combination therapy shows mixed results for device-related infections (DRIs). More research is needed to confirm its effectiveness against biofilm-forming bacteria in these complex cases.
Area of Science:
- Infectious Diseases
- Antimicrobial Therapy
- Medical Devices
Background:
- Rifampin is frequently used for device-related infections (DRIs) due to its anti-biofilm properties.
- Clinical evidence supporting rifampin's efficacy in DRIs has historically been limited.
Purpose of the Study:
- To review contemporary evidence (2011-2023) on rifampin use for DRIs.
- To describe current findings and considerations for rifampin in treating these infections.
Main Methods:
- A systematic literature review of PubMed and Google Scholar was conducted.
- Studies evaluating systemic rifampin for DRIs published between 2011 and 2023 were included.
- References of identified studies were screened for additional relevant research.
Main Results:
- 48 out of 68 identified studies met inclusion criteria.
- Studies were predominantly retrospective and small, with diverse methodologies.
- Statistically significant evidence for rifampin combination efficacy was limited to prosthetic joint infections and one study on vascular graft infections.
Conclusions:
- Current literature presents conflicting evidence on the benefits of rifampin combination therapy for DRIs.
- Robust research is essential to definitively establish rifampin's role in managing DRIs.
